Modulation	0	10	O
of	11	13	O
angiogenesis	14	26	O
and	27	30	O
progelatinase	31	44	B-Gene_or_gene_product
a	45	46	I-Gene_or_gene_product
by	47	49	O
thrombin	50	58	B-Gene_or_gene_product
receptor	59	67	I-Gene_or_gene_product
mimetics	68	76	O
and	77	80	O
antagonists	81	92	O
.	92	93	O

The	95	98	O
angiogenic	99	109	O
action	110	116	O
of	117	119	O
thrombin	120	128	B-Gene_or_gene_product
has	129	132	O
been	133	137	O
shown	138	143	O
to	144	146	O
be	147	149	O
mediated	150	158	O
by	159	161	O
activation	162	172	O
of	173	175	O
the	176	179	O
thrombin	180	188	B-Gene_or_gene_product
receptor	189	197	I-Gene_or_gene_product
.	197	198	O

In	199	201	O
this	202	206	O
report	207	213	O
we	214	216	O
studied	217	224	O
the	225	228	O
effects	229	236	O
of	237	239	O
SFLLR	240	245	B-Gene_or_gene_product
,	245	246	O
an	247	249	O
agonist	250	257	O
of	258	260	O
the	261	264	O
activated	265	274	O
thrombin	275	283	B-Gene_or_gene_product
receptor	284	292	I-Gene_or_gene_product
and	293	296	O
thrombin	297	305	B-Gene_or_gene_product
receptor	306	314	I-Gene_or_gene_product
peptide	315	322	O
and	323	326	O
non	327	330	O
peptide	331	338	O
antagonists	339	350	O
on	351	353	O
angiogenesis	354	366	O
in	367	369	O
the	370	373	O
chick	374	379	B-Organism
chorioallantoic	380	395	B-Multi-tissue_structure
membrane	396	404	I-Multi-tissue_structure
(	405	406	O
CAM	406	409	B-Multi-tissue_structure
)	409	410	O
system	411	417	O
.	417	418	O

As	419	421	O
antagonists	422	433	O
were	434	438	O
used	439	443	O
the	444	447	O
tripeptide	448	458	B-Gene_or_gene_product
FPR	459	462	I-Gene_or_gene_product
and	463	466	O
non	467	470	O
-	470	471	O
peptide	471	478	O
1	479	480	B-Drug_or_compound
,	480	481	I-Drug_or_compound
4	481	482	I-Drug_or_compound
-	482	483	I-Drug_or_compound
disubstituted	483	496	I-Drug_or_compound
piperazine	497	507	I-Drug_or_compound
derivatives	508	519	I-Drug_or_compound
.	519	520	O

The	521	524	O
pentapeptide	525	537	B-Gene_or_gene_product
SFLLR	538	543	I-Gene_or_gene_product
,	543	544	O
like	545	549	O
thrombin	550	558	B-Gene_or_gene_product
,	558	559	O
caused	560	566	O
a	567	568	O
marked	569	575	O
stimulation	576	587	O
of	588	590	O
angiogenesis	591	603	O
in	604	606	O
the	607	610	O
CAM	611	614	B-Multi-tissue_structure
.	614	615	O

FPR	616	619	B-Gene_or_gene_product
and	620	623	O
the	624	627	O
piperazine	628	638	B-Drug_or_compound
derivatives	639	650	I-Drug_or_compound
caused	651	657	O
suppression	658	669	O
of	670	672	O
angiogenesis	673	685	O
and	686	689	O
in	690	692	O
combination	693	704	O
with	705	709	O
thrombin	710	718	B-Gene_or_gene_product
antagonized	719	730	O
its	731	734	O
angiogenic	735	745	O
effect	746	752	O
.	752	753	O

Thrombin	754	762	B-Gene_or_gene_product
and	763	766	O
SFLLR	767	772	B-Gene_or_gene_product
activated	773	782	O
progelatinase	783	796	B-Gene_or_gene_product
A	797	798	I-Gene_or_gene_product
(	799	800	O
MMP	800	803	B-Gene_or_gene_product
-	803	804	I-Gene_or_gene_product
2	804	805	I-Gene_or_gene_product
)	805	806	O
in	807	809	O
the	810	813	O
culture	814	821	O
medium	822	828	O
of	829	831	O
human	832	837	B-Cell
umbilical	838	847	I-Cell
cord	848	852	I-Cell
endothelial	853	864	I-Cell
cells	865	870	I-Cell
(	871	872	O
HUVECs	872	878	B-Cell
)	878	879	O
.	879	880	O

MMP	881	884	B-Gene_or_gene_product
-	884	885	I-Gene_or_gene_product
2	885	886	I-Gene_or_gene_product
is	887	889	O
involved	890	898	O
in	899	901	O
the	902	905	O
early	906	911	O
steps	912	917	O
of	918	920	O
angiogenesis	921	933	O
leading	934	941	O
to	942	944	O
local	945	950	O
dissolution	951	962	O
of	963	965	O
basement	966	974	B-Gene_or_gene_product
membrane	975	983	I-Gene_or_gene_product
collagen	984	992	I-Gene_or_gene_product
and	993	996	O
migration	997	1006	O
of	1007	1009	O
the	1010	1013	O
activated	1014	1023	O
endothelial	1024	1035	B-Cell
cells	1036	1041	I-Cell
.	1041	1042	O

FPR	1043	1046	B-Gene_or_gene_product
and	1047	1050	O
the	1051	1054	O
piperazine	1055	1065	B-Drug_or_compound
derivatives	1066	1077	I-Drug_or_compound
inhibited	1078	1087	O
the	1088	1091	O
activation	1092	1102	O
of	1103	1105	O
this	1106	1110	O
enzyme	1111	1117	O
.	1117	1118	O

They	1119	1123	O
also	1124	1128	O
antagonised	1129	1140	O
the	1141	1144	O
effects	1145	1152	O
of	1153	1155	O
both	1156	1160	O
thrombin	1161	1169	B-Gene_or_gene_product
and	1170	1173	O
SFLLR	1174	1179	B-Gene_or_gene_product
on	1180	1182	O
MMP	1183	1186	B-Gene_or_gene_product
-	1186	1187	I-Gene_or_gene_product
2	1187	1188	I-Gene_or_gene_product
activation	1189	1199	O
.	1199	1200	O

These	1201	1206	O
results	1207	1214	O
suggest	1215	1222	O
that	1223	1227	O
non	1228	1231	O
-	1231	1232	O
thrombogenic	1232	1244	O
agonists	1245	1253	O
or	1254	1256	O
antagonists	1257	1268	O
of	1269	1271	O
the	1272	1275	O
activated	1276	1285	O
thrombin	1286	1294	B-Gene_or_gene_product
receptor	1295	1303	I-Gene_or_gene_product
can	1304	1307	O
be	1308	1310	O
used	1311	1315	O
as	1316	1318	O
modulators	1319	1329	O
of	1330	1332	O
angiogenesis	1333	1345	O
.	1345	1346	O

